ACTRN12612000370808已完成未知
A prospective, single-masked (participant only), contralateral, single-group, controlled, balanced block design, non-dispensing clinical trial measuring global higher order aberrations and retinal image quality of commercial contact lenses with the EyeMapper.
Brien Holden Vision Institute0 个研究点目标入组 40 人开始时间: 2012年3月30日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 35 Years（—）
- 性别
- All
入选标准
- •Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent.
- •Be 18 to 35 years old, male or female.
- •Willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator.
- •Have ocular health findings considered to be normal” and which would not prevent the participant from safely wearing contact lenses.
- •Have a prescription that is myopic between -0.25 to -4.00D (inclusive).
- •May have astigmatism that is not greater than -1.00DC.
- •Be experienced or inexperienced at wearing contact lenses
排除标准
- •Any pre-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses.
- •Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjogrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants.
- •Use of or a need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial.
- •Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant’s ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial.
- •NB: Systemic antihistamines are allowed on an as needed basis”, provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used.
- •Eye surgery within 12 weeks immediately prior to enrolment for this trial.
- •Previous corneal refractive surgery.
- •Contraindications to contact lens wear.
- •Known allergy or intolerance to ingredients in any of the clinical trial products.
- •Currently enrolled in another clinical trial.
- •Participation in a clinical trial within the previous 2 weeks for long-term studies and 48 hours between short-term studies.
- •Pregnancy*.
- •*Formal testing of pregnancy is not required. A participant’s verbal report is sufficient.
研究者
相似试验
已完成
不适用
Accommodative Lag with Multifocal Contact LensesAccommodative lag responseEye - Normal eye development and functionACTRN12611001004954Brien Holden Vision Institute60
已完成
不适用
A trial to assess the visual performance of multifocal contact lenses when worn by adults who have age-related problems with their focussing.Eye - Diseases / disorders of the eyePresbyopiaACTRN12620001033932Menicon Co. Ltd., Japan26
尚未招募
不适用
Comparison of the subjective comfort of DAILIES TOTAL 1[RegisteredTradeMark] and ACUVUE[RegisteredTradeMark] OASYS[TradeMark] in twenty-five experienced contact lens wearers.Ocular comfort/discomfortEye - Normal eye development and functionACTRN12612000187842Brien Holden Vision Institute25
已完成
不适用
Clinical trial to assess the visual performance of prototype contact lenses for astigmatismAstigmatismACTRN12615001337561Brien Holden Vision Pty Ltd35
撤回
不适用
A short-term evaluation of the accommodative responses of 6 contact lenses for myopia control and a control lens.Ocular AccommodationEye - Diseases / disorders of the eyeMyopiaACTRN12618001790235Brien Holden Vision Institute57